Logo image of FBLG

FIBROBIOLOGICS INC (FBLG) Stock Price, Quote, News and Overview

NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD

1.22  -0.07 (-5.43%)

After market: 1.24 +0.02 (+1.64%)

FBLG Quote, Performance and Key Statistics

FIBROBIOLOGICS INC

NASDAQ:FBLG (4/25/2025, 8:04:36 PM)

After market: 1.24 +0.02 (+1.64%)

1.22

-0.07 (-5.43%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.59
52 Week Low0.76
Market Cap46.04M
Shares37.74M
Float29.57M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-31 2024-01-31


FBLG short term performance overview.The bars show the price performance of FBLG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

FBLG long term performance overview.The bars show the price performance of FBLG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of FBLG is 1.22 USD. In the past month the price increased by 19.61%. In the past year, price decreased by -87.93%.

FIBROBIOLOGICS INC / FBLG Daily stock chart

FBLG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About FBLG

Company Profile

FBLG logo image FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Company Info

FIBROBIOLOGICS INC

455 E. Medical Center Blvd, Suite 300

Houston TEXAS US

Employees: 10

Company Website: https://fibrobiologics.com/

Investor Relations: http://ir.fibrobiologics.com/sec-filings/all-sec-filings

Phone: 12816715150

FIBROBIOLOGICS INC / FBLG FAQ

What is the stock price of FIBROBIOLOGICS INC today?

The current stock price of FBLG is 1.22 USD. The price decreased by -5.43% in the last trading session.


What is the ticker symbol for FIBROBIOLOGICS INC stock?

The exchange symbol of FIBROBIOLOGICS INC is FBLG and it is listed on the Nasdaq exchange.


On which exchange is FBLG stock listed?

FBLG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FIBROBIOLOGICS INC stock?

9 analysts have analysed FBLG and the average price target is 10.97 USD. This implies a price increase of 798.77% is expected in the next year compared to the current price of 1.22. Check the FIBROBIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FIBROBIOLOGICS INC worth?

FIBROBIOLOGICS INC (FBLG) has a market capitalization of 46.04M USD. This makes FBLG a Nano Cap stock.


How many employees does FIBROBIOLOGICS INC have?

FIBROBIOLOGICS INC (FBLG) currently has 10 employees.


What are the support and resistance levels for FIBROBIOLOGICS INC (FBLG) stock?

FIBROBIOLOGICS INC (FBLG) has a resistance level at 1.28. Check the full technical report for a detailed analysis of FBLG support and resistance levels.


Should I buy FIBROBIOLOGICS INC (FBLG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FIBROBIOLOGICS INC (FBLG) stock pay dividends?

FBLG does not pay a dividend.


What is the Price/Earnings (PE) ratio of FIBROBIOLOGICS INC (FBLG)?

FIBROBIOLOGICS INC (FBLG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).


What is the Short Interest ratio of FIBROBIOLOGICS INC (FBLG) stock?

The outstanding short interest for FIBROBIOLOGICS INC (FBLG) is 7.61% of its float. Check the ownership tab for more information on the FBLG short interest.


FBLG Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to FBLG. When comparing the yearly performance of all stocks, FBLG is a bad performer in the overall market: 95.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

FBLG Financial Highlights

Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 49.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -67.87%
ROE -408.08%
Debt/Equity 3.35
Chartmill High Growth Momentum
EPS Q2Q%85.52%
Sales Q2Q%N/A
EPS 1Y (TTM)49.71%
Revenue 1Y (TTM)N/A

FBLG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to FBLG. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners16.95%
Ins Owners17.14%
Short Float %7.61%
Short Ratio9.03
Analysts
Analysts82.22
Price Target10.97 (799.18%)
EPS Next Y-28.43%
Revenue Next YearN/A